September was full of exciting news in the clinical trial and healthcare community, including partnerships, products, and promotions from Rho, Bracket, Hearst, and more. Hearst announced an equity investment in M2Gen one of the top comprehensive cancer centers in the United States.…
PureTech’s device could rival Saxenda in obesity market
A new non-invasive device from PureTech Health could help millions of overweight or obese people to slim down, allowing them to avoid surgery or prescription treatments. Analysts believe it could also rival Novo Nordisk, the pharmaceutical company whose products are…
In a world of change, big pharma remains a constant
Pfizer, Roche and Novartis top the pharma table – and are set to stay there until at least 2022. Novo Nordisk predicted to deliver the greatest return on investment. But cell and gene therapies, plus AI, digital tech will disrupt…
FDA is Advancing the Goals of the Orphan Drug Act
Three months ago, FDA committed to fully eliminate a backlog of about 200 orphan drug designation requests that were pending review with FDA, and to implement policies that would require FDA to respond to all new designation requests within 90…
Apple CEO pledges to put patients’ health before profits
Apple is looking at the broader healthcare ecosystem and not just those ventures that can make the firm money, according to CEO Tim Cook. The remarks were made in an interview with Fortune, a day before the company launches…
Facebook just held a breakfast to promote its ‘clinical trials strategy’ to drug marketers
Facebook brought drug marketers together to educate them on targeting consumers. The company is going after an industry that’s rapidly increasing its digital ad spending On Thursday, the company’s New York-based health unit hosted an invitation-only breakfast for pharmaceutical marketers…
Smartphone app looks to tackle US opioid crisis
A smartphone app could help improve pain and addiction management associated with America’s ongoing opioid crisis. According to the National Institutes of Health, more than 25 million – or over one in 10 – Americans experience pain daily. But…
Summit Therapeutics antibiotic delivers encouraging clinical trial results
A phase II clinical trial pitched Summit’s ridinilazole against a specialist (narrow-spectrum) drug, fidaxomicin Summit Therapeutics PLC’s (LON:SUMM, NASDAQ:SMMT) next-generation antibiotic scored well in a head to head with the existing treatment for Clostridium difficile infection (C.difficile). A phase II…
Clinerion, Novartis, RxEOB, And More: News From August 2017
August 31, 2017 | August was full of exciting news in the clinical trial and healthcare community, including partnerships and products from Clinerion, Novartis, RxEOB, and more. RxEOB has authored the case study, “Utilizing RxEOB MercuryMessaging to promote mammograms.” The RxEOB…
